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Drug discovery for psychiatric disorders using 
high-content single-cell screening of signaling network 
responses ex vivo
Santiago G. Lago1*, Jakub Tomasik1*, Geertje F. van Rees1, Hannah Steeb1, David A. Cox1, 
Nitin Rustogi1, Jordan M. Ramsey1, Joshua A. Bishop2, Tracey Petryshen3,4,5, Stephen J. Haggarty2, 
Javier Vázquez-Bourgon6,7,8, Sergi Papiol9,10,11, Paula Suarez-Pinilla6,7, Benedicto Crespo-Facorro6,7,8, 
Nico J. van Beveren12,13,14, Sabine Bahn1†
There is a paucity of efficacious new compounds to treat neuropsychiatric disorders. We present a novel approach 
to neuropsychiatric drug discovery based on high-content characterization of druggable signaling network 
responses at the single-cell level in patient-derived lymphocytes ex vivo. Primary T lymphocytes showed functional 
responses encompassing neuropsychiatric medications and central nervous system ligands at established (e.g., GSK-3) 
and emerging (e.g., CrkL) drug targets. Clinical application of the platform to schizophrenia patients over the course 
of antipsychotic treatment revealed therapeutic targets within the phospholipase C1–calcium signaling pathway. 
Compound library screening against the target phenotype identified subsets of L-type calcium channel blockers 
and corticosteroids as novel therapeutically relevant drug classes with corresponding activity in neuronal cells. 
The screening results were validated by predicting in vivo efficacy in an independent schizophrenia cohort. The 
approach has the potential to discern new drug targets and accelerate drug discovery and personalized medicine 
for neuropsychiatric conditions.
INTRODUCTION
In few areas of postgenomic drug discovery is the disconnect between 
improved scientific resources and the lack of novel drug entities as 
devastatingly apparent as in the case of neuropsychiatric disorders 
(1). Despite their enormous burden on worldwide health, accounting 
for 31% of years lived with disability and a lifetime prevalence of up to 
20% of the global population (2), drugs with novel mechanisms of 
action are lacking (1, 2). Derivatives of drugs found serendipitously 
over four decades ago (3), and thought to target brain monoamine 
receptors, are effective in only 40 to 60% of affected individuals 
(4, 5). This is largely due to a lack of understanding of the patho-
physiology of neuropsychiatric diseases, incomplete characteriza-
tion of the molecular targets of existing drugs, a scarcity of relevant 
preclinical models, and an inability to accurately predict clinical 
treatment response as a result of disease heterogeneity (1, 6).
Primary neuropsychiatric drug targets, such as the dopamine 
2 receptor (DRD2) or glutamate receptor subunit genes (GRM3, 
GRIN2A, and GRIA1) in schizophrenia (SCZ), have only recently 
been linked to genetic risk of disease at the population level through 
large-scale, genome-wide association studies (GWAS) (7). However, 
polygenic risk scores currently explain only a fraction of disease 
liability, e.g., 7% in SCZ (4) relative to up to 80% heritability derived 
from family and monozygotic twin studies (8). Putative individual 
GWAS risk alleles account only for a marginal increase in disease 
risk with odds ratios typically under 1.1 and differences in allele fre-
quencies between cases and controls less than 2% (4). The concept 
that each neuropsychiatric patient has a different combination of 
multiple common risk alleles, each with a small incremental contri-
bution, has led to the use of in silico pathway analysis to identify cell 
signaling pathways that represent convergent drug targets (1, 4, 7). 
Although recent expression of quantitative trait loci and transcriptome- 
wide association studies have provided a means for prioritizing 
neuropsychiatric GWAS risk loci (9), there remains a formidable 
challenge in summarizing the functional implications of these studies 
relative to the molecular and cellular complexity of the human nervous 
system (7).
Furthermore, because of the impracticalities of accessing live 
human brain tissue, there is a lack of relevant and scalable cellular 
models in which to empirically test cell signaling alterations and their 
interactions with novel pharmacological probes on the genomic 
background of neuropsychiatric disease. Neurons derived from 
induced pluripotent stem cells (iPSCs) of neuropsychiatric patients 
have partially addressed this issue (10). While the cost of the iPSC 
screening technologies has decreased relative to increased throughput, 
challenges in end fate specificity, technical variation, and attrition 
of donor phenotypes continue to hinder the differentiation process 
(11) and limit the application of these models to comprehensive 
drug screening. In contrast, peripheral blood mononuclear cells 
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(PBMCs) are a physiologically relevant and readily accessible primary 
tissue amenable to high-content functional analysis (12, 13). Recent 
work suggests that neuropsychiatric diseases are systemic disorders 
resulting from disruption of cell signaling networks with parallel 
manifestations in both the brain and peripheral tissues (14, 15). 
PBMCs express many central nervous system (CNS) receptors 
and downstream signaling proteins that are implicated in neuro-
psychiatric disorders (16). Subsets of protein alterations common to 
both cell lineages have been associated with disease status, symptom 
severity, and therapeutic efficacy (17–19). Furthermore, recent GWAS 
data suggest the enrichment of single-nucleotide polymorphisms 
(SNPs) associated with neuropsychiatric (SCZ) risk loci within 
PBMC subtype–specific gene expression enhancers (7) and the 
coexpression of neuropsychiatric genetic risk phenotypes in both 
peripheral and CNS tissues (20, 21). Although the functional corre-
spondence between shared signaling motifs in PBMCs and CNS cells 
remains to be fully explored, it is possible that subsets of pathways, 
or even individual protein-protein interactions, which do overlap, 
are clinically relevant and can be practically exploited for drug dis-
covery. Moreover, evidence that peripheral alterations can induce 
functional changes in the CNS with corresponding behavioral 
symptomatology [e.g., psychotic symptoms linked to gut microbiome 
alterations (22) or depressive-like symptoms following proinflam-
matory cytokine release during microbial infection (23)] suggests that 
peripheral cellular models may not solely be confined to surrogate 
identification of CNS targets but may also represent underlying 
pathophysiological mechanisms.
Exploration of neuropsychiatric patient PBMCs, with regard to 
functional alterations that reflect the disease state, could have 
important implications for overcoming current obstacles in neuro-
psychiatric drug discovery. First, the use of primary patient cells in 
the early stages of the drug discovery pipeline is associated with a 
higher success rate for putative targets and compounds (24). Second, 
the use of functional testing in live cells enables the elucidation of 
relevant disease-specific alterations in cell signaling networks, 
which are not observable simply by quantification of protein levels in 
their basal state, including homeostatic and regulatory mechanisms 
(13). Third, the focus on cellular responses provides the opportunity 
to summarize complex genetic risk factors with heterogeneous 
manifestations as integrated phenotypes, which are more amenable 
to drug screening and clinical treatment response prediction (25). 
Last, targeting of key cellular functional transducers, such as G protein– 
coupled receptors, receptor tyrosine kinases, ion channels, and protein 
kinases and phosphatases, represents a heuristic method for screening 
of the most “druggable” part of the genome (26).
Here, we apply high-content single-cell screening of functional 
ligand-receptor interactions and downstream signaling mechanisms 
(27, 28) in PBMCs from neuropsychiatric patients and controls 
ex vivo (Fig. 1). Using fluorescent cell barcoding (27), automated 
sample preparation, and multiparameter phospho-specific flow 
cytometry (28), we measure the activation of up to 78 intracellular 
signaling epitopes in parallel [spanning key CNS and immune cell 
signaling pathways such as Akt/GSK-3 (glycogen synthase kinase 3), 
PKA (protein kinase A), PKC, MAPK (mitogen-activated protein 
kinase), JAK (Janus kinase)/STAT (signal transducers and activators 
of transcription), IL-1R (interleukin-1 receptor)/TLR (Toll-like 
receptor), and TCR/BCR (T/B cell receptor) signaling] in response 
to 70 functional ligands (including CNS receptor agonists, neuro-
psychiatric medications, cytokines, hormones, growth factors, anti-
gens, and intracellular signaling modulators) in primary PBMCs. 
We use a mixture of endogenous ligands and exogenous cellular 
stimulants to provide a balance of physiological relevance, receptor 
subtype specificity, potency, and heuristic targeting of the maximum 
number of downstream signaling alterations in limited clinical 
samples. This generates readouts for a total of 5460 ligand-epitope 
combinations (nodes), or parallel functional assays, conducted in 
an individual PBMC sample. We explore the utility of this functional 
array for neuropsychiatric drug discovery in four stages. First, we 
define the kinetic profile of cell signaling network responses to CNS 
ligands and known neuropsychiatric treatments in PBMCs from 
control donors [kinetic profiling (KP); Fig. 1B]. Second, we identify 
cell signaling responses, which are altered in PBMCs from drug-
naïve patients with SCZ relative to controls and are subsequently 
normalized by efficacious clinical treatment in vivo [drug target 
identification (TI); Fig. 1C]. Third, we use the disease-associated 
cell signaling responses as the basis for phenotypic screening of 
U.S. Food and Drug Administration (FDA)–approved and experi-
mental drugs capable of normalizing the aberrant cellular responses 
in PBMCs and neurons [drug repurposing (DR); Fig. 1D]. Last, we 
validate the clinical significance of the screening results by correlating 
the cellular activity of a subset of compounds with their in vivo efficacy 
in an independent cohort of drug-naïve patients with SCZ [clinical 
validation (CV); Fig. 1E]. Together, our platform provides a novel 
patient-centric paradigm for performing pharmacological studies 
and drug discovery for neuropsychiatric disorders.
RESULTS
T lymphocytes as a surrogate model for kinetic drug 
interactions at CNS drug targets
We evaluated the potential of multiplexed phospho-specific flow 
cytometry (27, 28) for investigating signaling responses relevant to 
neuropsychiatric disorders in PBMCs in three stages. We focused on 
T lymphocytes (CD3+) as the most abundant (40 to 60%) PBMC subtype. 
First, we set up and tested the platform for reproducibility and dynamic 
range. We used induction of Stat3 (pY705) phosphorylation by IL-6 at 
15 min as a model response [based on previously reported findings in 
phospho-specific flow cytometry (27, 28) and IL-6 serum alterations in 
SCZ (14)] and assessed whether cell signaling responses could be 
measured with precision independently of the position of the ligand 
within the barcoding matrix (n = 80 barcodes; figs. S1 and S2) and 
the antibody detection fluorophore (mean CV, 6%; mean Z′ factor, 
0.65; figs. S3 and S4). Next, we assessed the variation in signaling 
responses across a subset of 3696 nodes (readouts from 56 compounds 
at 66 epitopes; tables S1 and S2) in PBMCs from the same healthy 
donor measured across six different experimental runs (mean CV per 
node, 11%; fig. S5A). Last, we compared functional responses in the 
above nodes between two independent cohorts of healthy PBMC 
donors from different collection sites (n = 8 and 12, respectively), 
which showed 75% overall replication of active nodes (100% replication 
for the JAK/STAT pathway and 85% replication for the Akt/GSK-3 
pathway) and correlated fold changes (FCs; Spearman’s rank correlation 
coefficient rs = 0.94, P < 1 × 10−15; fig. S5B). Antibody stain indices 
[ratio of the median fluorescence intensity (MFI) in stained versus 
unstained vehicle condition across PBMC donors] at each epitope (fig. S6) 
were also reproduced between cohorts (rs = 0.96, P < 1 × 10−15; fig. S5C).
Among the selected time points [based on published data for 
prototypical T cell and CNS cell signaling responses (12, 28–31)] 
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measured for the initial set of 5460 nodes (responses at 78 epitopes to 
70 compounds at concentrations relevant to in vitro efficacy and clinical 
serum levels; Fig. 2, A and B, and tables S1 and S2), we observed 
maximal induction of significant cell signaling responses (P < 0.05, 
Wilcoxon rank sum test) at 30 min, where 228 of 5460 nodes were 
active, compared to 97, 146, and 211 nodes at 1, 5, and 15 min, 
respectively (Fig. 2, C and D, figs. S7 and S8, and tables S3 and S4). 
Although no time points longer than 30 min were tested, this kinetic 
profile is consistent with published data, which indicates maximal 
induction of phosphorylation of cell signaling proteins using 
conventional PBMC ligands at 30 min (12). The distribution of 
significant nodes with respect to ligand or epitope class was largely 
preserved across time points, such that 30 min represented the 
maximal induction of nodes for most classes within the time points 
tested (Fig. 2, C and D). Moreover, we observed widespread changes 
in cell signaling epitope expression for positive controls calyculin, 
phorbol 12-myristate 13-acetate (PMA)/ionomycin, thapsigargin, 
and staurosporine (table S3), in addition to dynamic regulation of 
key JAK/STAT signaling epitopes in response to immunomodulatory 
cytokines (fig. S9) at 30 min, consistent with published data (12, 31). 
Thus, we selected 30 min as the optimal time point of the four tested 
for the exploration of cell signaling nodes in clinical samples. To 
optimize use of the assay for clinical samples, in which cell numbers 
are limited, we excluded 14 ligands and 12 epitopes, which showed 
minimal activity at 30 min (tables S1 to S4), from the subsequent 
clinical study. This represented a reduction of the size of the functional 
matrix by a third and ensured that only the nodes with greater 
functionality, and hence greater potential for revealing disease- 
related drug targets, were carried forward to the clinical application 
of the platform.
Second, we evaluated the kinetic profiles of compounds known 
to interact with CNS pathways and compared them to the effects 
of established neuropsychiatric drugs and novel drug candidates. 
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Fig. 1. Ex vivo CNS drug discovery pipeline. (A) Human primary PBMCs provide an accessible ex vivo model of physiological single-cell phenotypes in health and 
disease. (B) Time-course exploration of responses to 70 ligands (including CNS ligands and neuropsychiatric treatments) across 78 diverse cell signaling epitopes (5460 
responses in total) in T cells from healthy control donors (n = 8) at 1, 5, 15, and 30 min ligand incubation times. (C) Identification of functional drug targets by comparing 
the T cell signaling response profiles of 56 ligands across 66 cell signaling epitopes (3696 responses) in PBMC samples from three clinical groups: healthy controls (n = 12), 
antipsychotic drug-naïve patients with SCZ (SCZ; n = 12), and the same patients following 6 weeks of clinical treatment with the atypical antipsychotic olanzapine (SCZ + AP; 
n = 10). (D) Modeling of disease-associated cellular responses and screening of U.S. Food and Drug Administration (FDA)–approved drugs (repurposing) and experimental 
neuropsychiatric compounds (n = 946 in total) in T cells from healthy control PBMC donors (n = 6 to 12) and human SH-SY5Y neuronal cells. (E) Validation of the ex vivo 
cellular model relative to in vivo clinical efficacy in an independent cohort of drug-naïve patients with SCZ (n = 30) treated with two of the study compounds. (F) Experimental 
design: PBMCs from each donor were distributed across a ligand library (A to O) and stimulated for 1 to 30 min at 37°C. Each ligand or vehicle well was stained with a 
unique combination of fluorescent barcoding dyes. Ligand wells were pooled and distributed across an array of antibodies (01 to 15) targeting specific phosphorylation 
or total protein sites on different intracellular signaling proteins. Changes in the activation status of the cell signaling proteins were analyzed at the single-cell level using 
flow cytometry for each donor individually. Assay plate dimensions are restricted to 15 wells for representation; full dimensions are detailed in brackets.
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Fig. 2. Kinetic distribution of T cell signaling responses across ligand and epitope categories. (A) Composition of the ligand array by class and (B) the epitope array by pathway. 
Number of ligands and epitopes per class is given in brackets. (C) Composition of the total number of significant responses (“nodes”; permuted P < 0.05, Wilcoxon rank sum test; 
minimum FC 10%) for each time point by ligand class and (D) by epitope pathway. (E) Significant kinetic responses (permuted P < 0.05, Wilcoxon rank sum test; sustained in the same 
direction for minimum two consecutive time points) to CNS ligands and (F) neuropsychiatric treatments. Legend shows the mean FC in epitope expression across significant time 
points, calculated per time point as median MFI of the ligand treatment/median MFI of the vehicle treatment across PBMC donors, with labels distributed evenly across the quantile 
range for negative and positive FCs separately. For down-regulated epitopes, legend shows −1/FC. Compounds and epitopes in the heat maps are ordered by the number of 
significant nodes across the time points. Targets of the CNS ligands include phencyclidine (an N-methyl-d-aspartate receptor antagonist/D2 receptor agonist/ receptor agonist), 
NECA (5’-N-ethylcarboxamidoadenosine; an adenosine A1/2A/3 receptor agonist), SR 57227 (a 5-HT3 receptor agonist), AS 19 (a 5-HT7 receptor agonist), and 7-OH-DPAT (a D3 receptor 
agonist). Clinical indications of the neuropsychiatric treatments include desipramine and fluoxetine (antidepressants), lithium and valproic acid (mood stabilizers), and clozapine, 
risperidone, aripiprazole, and haloperidol (antipsychotics). All data represent eight healthy control PBMC donors. CREB, cyclic adenosine monophosphate response element–binding 
protein; PDPK1, 3-phosphoinositide-dependent protein kinase-1; MEK1, MAPK kinase 1; PLC-2, phospholipase C2; Rb, retinoblastoma protein; NF-B, nuclear factor B.
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implicated cell signaling pathways in neuropsychiatric drug discovery 
(32). The reference pathway activation range (i.e., maximum positive or 
negative FC in epitope expression in response to ligand stimulation) was 
defined using positive controls. Calyculin (a phosphatase inhibitor) 
and the PMA/ionomycin cocktail (a PKC activator/calcium flux 
inducer) caused widespread induction of the epitopes within the 
canonical signaling pathway, with incremental responses at later 
time points, while staurosporine (a nonselective protein kinase 
inhibitor) showed the opposite effect (Fig. 3A). We also examined 
the effects of specific inhibitors. GSK 690693 (a specific Akt inhibitor) 
inhibited phosphorylation downstream of Akt1 at GSK-3 (pS9), 
rapamycin [a specific mTORC1 (mammalian target of rapamycin 
complex 1) complex inhibitor] inhibited phosphorylation downstream 
of mTORC1 at 4EBP1 (pT36/pT45), and CHIR-99021 (a highly 
selective GSK-3 inhibitor) displayed inhibition of phosphorylation 
directly at the pS9 residue on GSK-3 (Fig. 3A).
Several compounds used clinically to treat neuropsychiatric 
disorders displayed kinetic inhibition profiles, which overlapped 
with those described for GSK 690693, rapamycin, and CHIR-99021 
(Fig. 3A). Antidepressant medications fluoxetine and desipramine 
showed significant inhibition of phosphorylation at both GSK-3 
(pS9; maximum FCs, −1.48 and −1.35, respectively) and 4EBP1 
(pT36/pT45; maximum FCs, −1.54 and −1.35, respectively). Anti-
psychotic medications aripiprazole and risperidone inhibited phos-
phorylation at either GSK-3 (pS9; maximum FC, −1.20) or 4EBP1 
(pT36/pT45; maximum FC, −1.53), respectively. The mood stabi-
lizer lithium exhibited phosphorylation inhibition at 4EBP1 (pT36/
pT45; maximum FC, −1.25) but not at either of the GSK-3 phospho- 
epitopes. However, several of these psychoactive drugs also displayed 
inhibitory effects on phosphorylation at key sites of other Akt/GSK-3 
signaling proteins. For example, lithium showed inhibition at PDPK1 
(pS241; maximum FC, −1.05), aripiprazole at Akt (pT308; maximum 
FC, −1.09), and desipramine at nuclear factor B p65 (pS529; maximum 
FC, −1.27). In contrast, JB1121, a member of the recently found 
series of highly selective tricyclic pyrazolo-tetrahydroquinolinone 
GSK-3 inhibitors, developed as candidates for treatment-resistant bipolar 
disorder and other neuropsychiatric disorders with dysregulated GSK-3 
signaling (e.g., fragile X syndrome) (33), showed highly selective 
(−1.27- to −1.41-fold) phosphorylation inhibition of GSK-3 (pS9) 
across all the time points with no inhibition at any of the other 
selected pathway sites. This profile closely matched that of CHIR-99021, 
one of the most potent and selective GSK-3 inhibitors available (34). 
These data demonstrate multitarget modulation of known neuro-
psychiatric treatments, a property that is considered key to their 
therapeutic profile (35), in relevant CNS pathways ex vivo. Furthermore, 
it is possible to identify novel drug leads (CHIR-99021 and JB1121) 
or repurposing candidates currently indicated for other diseases 
(rapamycin) with enhanced specificity for putative neuropsychiatric 
target epitopes (Fig. 3, B and C).
Third, we examined the activities of CNS ligands and neuropsychiatric 
treatments across the full array of cell signaling epitopes. Kinetic 
screening of the cell signaling repertoire revealed 59 significant responses 
(FC, −1.28 to 1.35) for CNS receptor ligands at different time points. 
We prioritized the most robust responses as those with activity at a 
minimum of two consecutive time points in the same direction. Seven 
nodes fulfilled these criteria (Fig. 2E), including adenosine receptor 
agonist NECA/CREB [cyclic adenosine monophosphate (cAMP) 
response element–binding protein] (pS133)–ATF-1 (activating tran-
scription factor 1) (pS63; mean FC, 1.25 for 5 to 30 min), D3 receptor 
agonist 7-OH-DPAT/MAPK kinase 1 (MEK1) (pS298; mean FC, 
1.26 for 5 to 15 min), N-methyl-d-aspartate receptor antagonist 
phencyclidine/CrkL (pY207; mean FC, 1.10 for 1 to 5 min), and 5-HT3 
receptor agonist SR 57227/S6 (pS240; mean FC, 1.15 for 15 to 30 min).
Similar prioritization of the cell signaling interactions outside of the 
Akt/GSK-3 pathway for drugs used in different neuropsychiatric 
indications revealed multiple kinetic responses in T cells, which 
reflect potentially novel or emerging neuropsychiatric drug targets 
(Fig. 2F). Both typical (haloperidol) and atypical (clozapine) anti-
psychotics increased the phosphorylation of CrkL (pY207; mean 
FCs, 1.12 and 1.11 for 1 to 5 min, respectively), a protein encoded by 
a gene within a SCZ risk locus (36) and previously unknown as a 
target of antipsychotic medication. In the case of the mood stabilizers, 
the specific induction of Rb (pS780) phosphorylation by valproic 
acid (mean FC, 1.11 for 15 to 30 min) is consistent with its role 
as a histone deacetylase inhibitor, a feature that distinguishes its 
putative mechanism of action from that of lithium (37). In contrast, 
the effect of lithium in decreasing Smad2 (pS465/pS467)/Smad3 
(pS423/pS425) phosphorylation (mean FC, −1.16 for 15 to 30 min) 
is noteworthy in the context of the implication of Smad3 poly-
morphisms in antidepressant response latency (38). Similarly, the 
induction of MEK1 (pS298) phosphorylation by the antidepres-
sant desipramine (mean FC, 1.90 for 5 to 30 min) is consistent with 
previous reports (39). The current data suggest that the above 
compound- epitope interactions reflect emerging mechanisms of 
action of these compounds in the CNS, which can be tracked in periph-
eral blood cells.
Drug target discovery using an in vivo antipsychotic 
intervention study design
To test the suitability of the platform for neuropsychiatric drug target 
discovery, we used SCZ as a model disease and compared responses 
to 56 compounds at 66 epitopes at 30 min, in addition to 66 basal 
epitope levels (n = 3762 nodes in total; figs. S10 and S11 and tables 
S1 and S2), in T cells across three clinical groups—healthy controls 
(n = 12), antipsychotic drug-naïve patients with SCZ before treat-
ment (n = 12), and the same patients with SCZ after 6 weeks of 
clinical treatment with the atypical antipsychotic olanzapine (n = 10; 
fig. S12 and table S5). Three hundred thirty-five nodes, including 
48 basal epitopes and 287 ligand responses, satisfied the activity 
criteria of a minimum epitope stain index of two and, additionally, 
for ligand responses, a significant FC (P < 0.05, Wilcoxon rank sum 
test) of minimum 10% in at least one of the comparison groups. Of 
these, across both group comparisons (pretreatment SCZ versus 
healthy controls and pretreatment SCZ versus posttreatment SCZ), 
a total of 32 ligand responses and seven basal epitope levels were 
found to be significantly altered [P < 0.05, analysis of covariance 
(ANCOVA); Fig. 4, fig. S13, and tables S6 and S7], representing 
1.0% of the conditions screened and 11.6% of active nodes. Notably, 
all the nodes significantly associated with disease in the pretreat-
ment SCZ versus healthy control comparison and most of the nodes 
altered in the pretreatment versus posttreatment SCZ comparison 
(20 of 27 nodes) were functional responses to ligands, as opposed to 
changes in basal epitope expression. Six of the involved epitopes 
[CrkL (pY207), Pyk2 (pY402), Src (pY418), PKA RII (pS99), Akt1, and 
PLC-1 (phospholipase C1)] have been previously shown to display 
altered functional connectivity in CD4+ T cells in SCZ (13). These 
results imply that there is a clinical representation of SCZ pathology and 
antipsychotic treatment effects within the T cell signaling repertoire, 
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Fig. 3. Kinetic exploration of neuropsychiatric treatments and novel inhibitors of the Akt/GSK-3 pathway in T cells. (A) Kinetic induction of responses (left) at key 
Akt/GSK-3 pathway epitopes (right) for positive controls (calyculin A, PMA/ionomycin, staurosporine, and GSK 690693) as compared to neuropsychiatric treatments 
(fluoxetine, desipramine, risperidone, lithium, and aripiprazole) and specific novel inhibitors (rapamycin, CHIR-99021, and JB1121). Only significant responses (permuted 
P < 0.05, Wilcoxon rank sum test; n = 8 healthy control PBMC donors) are shown. Black dots at 30-min time points represent replication in an independent PBMC cohort 
(n = 12). Legend shows FC in epitope expression (calculated as median MFI of the ligand treatment/median MFI of the vehicle treatment across PBMC donors), with labels 
distributed evenly across the quantile range for negative and positive FCs separately. FC is converted to −1/FC for down-regulated epitopes. Proteins are colored with 
respect to their cellular function: blue (kinase), red (translation), and green (transcription). The position of mTORC1 is shown for mechanistic interpretation, although no 
epitopes were measured on this protein. (B and C) Inhibition potency and selectivity across all 70 ligands used in the time course for targets (B) GSK-3 (pS9) and (C) 4EBP1 
(pT36/pT45) at 30 min. Potency reflects the percentage of inhibition of phosphorylation at target site calculated as (1 − MFI of the ligand treatment/mean MFI of the vehicle 
treatment) × 100%, averaged across PBMC donors (n = 8). Selectivity reflects the ratio of the percentage of inhibition of phosphorylation at target site to mean percentage 
of inhibition across Akt (pS473), Akt (pT308), GSK-3 (pS9), and 4EBP1 (pT36/pT45) sites, averaged across eight donors. Only ligands with >10% potency are shown.
Lago et al., Sci. Adv. 2019; 5 : eaau9093     8 May 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
7 of 18
which is more readily observable in the presence of functional ligand 
stimulation.
To identify nodes representing potential drug targets, we assessed 
which of the cell signaling alterations present in pretreatment SCZ 
compared to healthy control samples were reversed (“normalized”) 
over the course of long-term clinical olanzapine treatment and were 
supported by existing large-scale genetic screening evidence. Of 14 cell 
signaling nodes associated with disease in the SCZ versus control 
comparison, we found two nodes (14%) to be reversed after clinical 
treatment (Fig. 4). Considering that the number of clinically associated 
nodes was 4.2% (14 of 335 nodes) and 8.1% (27 of 335 nodes) of the 
total active nodes assayed for SCZ versus control and olanzapine 
treatment comparisons, respectively, this represents a significant 
enrichment of nodes for which the signaling profile was reversed 
(P = 1.7 × 10−3). The reversal nodes included ligand responses to 
calcium mobilizer thapsigargin at PLC-1 and cAMP inducer forskolin 
at Pyk2 (pY402) and also remained significant after controlling 
for variables (smoking and alcohol consumption), which differed 
between the groups (table S5).
Thapsigargin/PLC-1 was the most significant ligand response 
altered in pretreatment SCZ compared to the healthy control group 
(P = 0.0001, Q = 0.018, two-way ANCOVA; table S6). Furthermore, 
these alterations were not due to existing differences in the levels of 
PLC-1, as basal expression of PLC-1 was not altered in either of 
the clinical group comparisons. This is in line with putative calcium 
signaling dysfunction in SCZ as suggested by GWAS and exome 
sequencing studies, which implicate a range of calcium signaling 
genes, including sarcoplasmic/endoplasmic reticulum calcium adeno-
sine triphosphatase 2 (ATP2A2) and voltage-gated calcium channel 
subunit genes (e.g., CACNA1C, CACNB2, and CACNA1I), among 
the foremost SCZ risk loci (7, 40). Subsets of these calcium channel 
subunits are expressed in T cells at levels comparable to excitable 
cells such as neurons and have been shown to modulate responses to 
thapsigargin (41). For the calcium pump ATP2A2, which is a direct 
target of thapsigargin, we observed a significant association between 
the genome-wide significant SCZ risk SNP rs4766428 (C > T) in the 
ATP2A2 gene (7) and the attenuated response to thapsigargin at 


































































































































































































Fig. 4. Target identification by functional profiling of cell signaling abnormalities in SCZ T cells. The drug target was selected on the basis of the normalization of 
aberrant cell signaling responses following in vivo pharmacological antipsychotic therapy. Shown are clinically associated T cell signaling nodes (n = 39 of 3762 total nodes screened), 
defined as individual ligand-epitope combinations, which displayed a significant effect (permuted P < 0.05, ANCOVA) between clinical group status and either ligand response (n = 32) or 
basal epitope expression (n = 7). All nodes were filtered for a minimum stain index of 2 and, for ligand responses, a significant (permuted P < 0.05, Wilcoxon rank sum test) FC of minimum 
10% in at least one of the comparison groups. Nodes altered in the SCZ versus healthy control (n = 12 PBMC donors per group) or SCZ (n = 12) versus SCZ + antipsychotic (n = 10) group 
comparisons are shown in red and blue, respectively. Nodes altered in both comparisons in opposite directions (i.e., “reversed”) are shown in yellow. The yellow nodes represent putative 
normalization of SCZ cell signaling alterations following efficacious clinical treatment (fig. S12) and form the basis for drug target selection. Nodes are grouped by signaling pathway (top) and 
ligand class (left). Refer to tables S6 and S7 and fig. S13 for a detailed group comparison. IRS-1, insulin receptor substrate 1; WIP, Wiskott-Adrich syndrome protein (WASP)-Interacting Protein. 
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a point of convergence between the genetic and functional screening 
results. Mutations in ATP2A2 also cause Darier disease, which 
cosegregates with SCZ, bipolar disorder, and affective psychosis in 
some cases and families, and are associated with neuropsychiatric 
disease severity (20). Concurrently, PLC isotypes (PLCB2, PLCL1, 
and PLCH2) have been implicated as primary SCZ risk loci (7) with 
altered expression in the brain of patients with SCZ postmortem 
(PLCB1) and SCZ-like behavioral abnormalities in knockout animal 
models (PLCG1 and PLCB1) (42, 43). The response elicited by 
thapsigargin, increased cytosolic calcium concentrations and changes 
in PLC-1 expression, is common to many endogenous ligands and 
signaling mechanisms implicated in SCZ (44–46), including dopamine- 
glutamate interactions in the neuronal postsynaptic density (44, 47) 
and receptor tyrosine kinase signaling in response to neurotrophins 
(48, 49). These results implicate the thapsigargin/PLC-1 response 
as the primary novel drug target to emerge from the functional 
screening of cells of patients with SCZ (Fig. 5A and fig. S15).
Drug repurposing targeting disease-related functional 
cellular responses
On the basis of the functional response identified in SCZ patient 
T cells, we performed drug discovery and repurposing for SCZ 
in four stages (Fig. 5D). First, we modeled the attenuated T cell 
response to thapsigargin at PLC-1 ex vivo (figs. S16 and S17) and 
identified 102 compounds (of a total of 946; table S8) from the 
extended FDA-approved drug library that interacted with the 
thapsigargin/PLC-1 response [P < 0.05, two-way analysis of variance 
(ANOVA); Fig. 5B]. The top hits (P < 0.001, n = 18) were enriched 
for positive controls (calyculin, thapsigargin, and staurosporine) 
and calcium channel blockers (NNC 55-0396, penfluridol, loperamide, 
and nisoldipine), consistent with the established functions of the 
positive controls as broad-spectrum cell signaling modulators and 
the calcium channel blockers as mechanistic probes of calcium flux 
alterations. We subsequently identified a subset of 22 compounds, 
which displayed the selective potentiation profile (i.e., were inactive 
alone but potentiated the PLC-1 response selectively in the pres-
ence of thapsigargin; Fig. 5B, fig. S18, and table S9). These included 
nisoldipine as the top hit (P = 0.0002; 3.1-fold potentiation) and 
olanzapine (P = 0.009, ranked seventh; 2.9-fold potentiation), con-
sistent with the clinical results in patients. The hits were also en-
riched for cephalosporin antibiotics (23%), corticosteroids (18%), 
and retinoids (9%). Eight of the initial 22 hits were validated in pre-
liminary dose-response testing and were carried forward to the next 
stage, alongside 16 other members of the same therapeutic classes 
(calcium channel blockers, antipsychotic medications, cortico-
steroids, and antibiotics), which were included to explore potential 
structure-activity relationships (fig. S19).
In the second stage, using an extended dose-response range, we 
identified 10 compounds that showed selective potentiation of the 
PLC-1 response in the presence of thapsigargin, at concentrations 
below those that were active in the vehicle condition alone, indicating 
a potential therapeutic window (2.8 to 156.7 M difference in 20% 
maximal inhibitory concentration, depending on the compound; 
fig. S20). The selective thapsigargin/PLC-1 potentiation profile of 
olanzapine was also shared by other atypical antipsychotic drugs 
(risperidone, aripiprazole, and clozapine), but not typical antipsychotics 
(haloperidol and penfluridol), consistent with differential effects of 
typical versus atypical antipsychotics on thapsigargin-induced calcium 
mobilization from the endoplasmic reticulum in vitro (46). Selective 
potentiation was also observed for 1,4-dihydropyridine (DHP) L-type 
calcium channel blockers with extended ester substitutions at the 
3-position of the pyridine ring (nimodipine, nisoldipine, and 
nicardipine) but not for the other members of the DHP class (no 
effect for nilvadipine; potentiation without therapeutic window for 
nifedipine; opposing effects for amlodipine), the phenylalkylamine 
L-type calcium channel blocker (verapamil), or highly specific T-type 
calcium channel blockers (NNC 55-0396 and penfluridol). The last 
three compounds, which showed the selective potentiation profile, 
were the corticosteroids, methylprednisolone and flunisolide, and the 
potassium channel blocker, ibutilide. Three compounds showed a 
broader selectivity window than any of the measured antipsychotic drugs 
(maximum of 20.8 M for olanzapine), namely, methylprednisolone 
(156.7 M), nisoldipine (43.4 M), and ibutilide (37.1 M).
In the third stage, we ranked the compounds that showed the 
selective potentiation profile in terms of their potency to shift the 
half maximal effective concentration (EC50) of thapsigargin/PLC-1 
dose-response curves at 10 M concentration, on average 10 times 
higher than therapeutic plasma levels (50), to ensure adequate dosing 
in the 30-min time window and account for serum protein drug 
binding. Consistent with the previous results, all 10 drugs decreased 
the EC50 of the thapsigargin/PLC-1 response compared to the 
vehicle condition (Fig. 5C). The second-generation antipsychotics 
displayed a rank order of potency ranging from risperidone (EC50, 
223 nM) to aripiprazole (233 nM), olanzapine (270 nM), and 
clozapine (311 nM). Furthermore, three drugs, namely, nicardipine 
(151 nM), nisoldipine (168 nM), and methylprednisolone (200 nM), 
showed stronger potentiation of the response than any of the mea-
sured antipsychotic medications. The effect of ibutilide (258 nM), 
flunisolide (286 nM), and nimodipine (290 nM) was within the 
range of the atypical antipsychotic medications.
Last, we validated the activity of the top two novel drug candidates 
(nisoldipine and nicardipine), in addition to the original clinical 
compound (olanzapine) as a positive control, at 10 M concentration 
in III-tubulin–positive human SH-SY5Y neuronal cells (fig. S21). 
We observed potentiation of the thapsigargin/PLC-1 response 
(circa EC50; fig. S21) for all three compounds (Fig. 6) with similar 
(nicardipine, 2.1-fold; nisoldipine, 2.4-fold) or greater (olanzapine, 
4.3-fold) FCs relative to those observed in PBMCs. Together, these 
results demonstrate the potential of the ex vivo platform to func-
tionally stratify current SCZ medications, in terms of their ability to 
ameliorate disease-associated cellular responses, and, moreover, 
identify structurally diverse novel drug indications with activity in 
neuronal cells.
Clinical drug target validation using ex vivo functional 
cellular responses
To investigate the relevance of the functional drug target (thapsigargin/
PLC-1) in relation to changes in psychopathology in patients and 
also explore its potential for personalized medicine applications, we 
correlated the ex vivo activity of two of the atypical antipsychotics 
identified in the DR stage (aripiprazole and risperidone) with their 
in vivo efficacy in a cohort of drug-naïve patients with SCZ who 
were longitudinally followed up over their treatment course (n = 30; 
table S10). Similar to the responses in PBMCs from healthy control 
donors, both compounds potentiated the thapsigargin/PLC-1 
response at 10 M in T cells from drug-naïve patients with SCZ 
ex vivo (Fig. 7). Furthermore, the shift in thapsigargin/PLC-1 EC50 
evoked by each compound in T cells from patients before clinical 
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treatment (0 weeks) was significantly associated with, and predictive 
of (P = 0.001 and 0.041, Q = 0.007 and 0.213, linear regression model; 
table S11), subsequent changes in positive symptomatology [Scale 
for the Assessment of Positive Symptoms (SAPS)] after 3 and 6 weeks 
of the respective drug administration in vivo (n = 12 aripiprazole, 
n = 18 risperidone; Fig. 7 and fig. S22A). The ex vivo readouts at 
0 weeks for either drug were not associated with changes in negative 
symptomatology at either of these clinical time points (fig. S22, B to 
D), consistent with the clinical profile of atypical antipsychotics that 
are focused mainly on the amelioration of positive (“psychotic”) 
symptoms. This is also in line with the reported role of PLC-1 dys-
function in behavioral changes linked to positive symptoms in ani-
mal models of neuropsychiatric diseases (42, 43). Other compounds 
identified in the DR stage, including novel candidate compounds 
(nisoldipine, nicardipine, and methylprednisolone) and an antipsychotic 
compound (olanzapine), also shared the ex vivo activity profile of the clin-
ical drugs (aripiprazole and risperidone) in PBMCs of drug-naïve patients 
with SCZ (fig. S23). Together, these findings suggest that the activity 
at the putative functional drug target identified in PBMCs is associated 
with clinical efficacy in treating characteristic subsets of SCZ symptoms 
in vivo. This supports the potential utility of the novel candidate 
compounds, which share the same mechanism of action at thapsigargin/
PLC-1, and raises the possibility of treatment response prediction 
for drugs that are currently indicated for SCZ.
DISCUSSION
Serendipitous clinical observations and structural improvement of 
existing treatments have been driving the field of neuropsychiatric 
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Fig. 5. Phenotypic drug repurposing based on cellular response. (A) Identification of functional cellular drug target. The attenuated response to thapsigargin at 
PLC-1 in T cells from drug-naïve patients with SCZ (permuted P = 0.0001, Q = 0.018, two-way ANCOVA), relative to healthy controls (CTRL), was reversed after 6 weeks of 
clinical treatment with the atypical antipsychotic drug olanzapine in vivo (permuted P = 0.017, Q = 0.340; n = 12 healthy controls, n = 12 drug-naïve patients with SCZ, and 
n = 10 patients with SCZ after antipsychotic treatment). Box plots show interquartile range with the median (horizontal line) and the minimum and maximum values 
(whiskers), excluding outliers (dots). (B) Results of primary drug screen. Permuted P values from thapsigargin drug interaction testing (two-way ANOVA; n = 6 to 12 healthy 
PBMC donors) are shown across the combined FDA-approved (n = 786) and experimental (n = 160) compound libraries. Dashed line represents threshold P value of 0.05. 
Significant hits are shown in green (n = 102), and compounds, which additionally showed selective potentiation of the thapsigargin/PLC-1 response (post hoc one-way 
ANOVA tests; fig. S18), are shown in magenta (n = 22; table S9). (C) Ranking of best selective potentiation candidates at 10 M concentration in terms of half maximal 
effective concentration (EC50) shifts in the thapsigargin/PLC-1 dose-response curve. Shown are mean values from six healthy PBMC donors (points) with SEM (vertical 
bars) and fitted four- parameter logistic curves. The y axis represents the MFI standardized as a proportion of minimum and maximum values. Legend shows the EC50 values 
with 95% confidence intervals (CI). Methylpred., methylprednisolone. (D) Distribution of drug classes across repurposing stages. Extended FDA-approved library screening 
(left) refers to the primary compound screen at a single dose (20 M unless otherwise specified in table S8) of compound (n = 946; B). Validation and selectivity testing 
(center) refer to dose- response titration (24 nM to 200 M) and validation of selective potentiation candidates and structural class relatives (n = 24; fig. S20; n = 6 healthy 
PBMC donors). Potentiation testing (right) refers to the titration of thapsigargin (12.5 pM to 20 M) in the presence of 10 M concentration of validated compounds (n = 10; 
C). In vivo effect of olanzapine (A) was reproduced in vitro throughout.
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(1–3). In this work, using an objective high-content screening approach for 
the functional characterization of signaling network responses in primary 
T cells ex vivo, we build on dynamic disease-related cellular phenotypes as a 
basis to explore novel therapeutic opportunities within the repertoire of ap-
proved drugs. The current findings have a number of potential implications 
for improved neuropsychiatric drug discovery and personalized medicine.
The elucidation ex vivo in primary patient samples of convergent 
abnormal cell signaling response phenotypes (“functional endophe-
notypes”) between neuropsychiatric patients with potentially varied 
genetic risk factors and environmental trajectories is the primary 
contribution of this work. It provides a tractable and accessible live 
cell model for de novo identification of drug candidates with novel 
Vehicle Vehicle Nicardipine Nisoldipine Olanzapine























































Fig. 6. Efficacy of top SCZ drug candidates in human SH-SY5Y neuronal cells. (A) Response to 30-min sub-EC50 (40 nM; fig. S21B) thapsigargin stimulation at PLC-1 
(yellow) in SH-SY5Y neuronal cells after a 45-min preincubation with the vehicle, top drug candidates (nisoldipine and nicardipine), or olanzapine (positive control) at 
10 M. Blue, 4′,6-diamidino-2-phenylindole (DAPI) (nuclei); magenta, III-tubulin (neuronal lineage marker). Scale bars, 100 m; 60× magnification. Representative of three 
replicate experiments imaged using confocal microscopy at identical laser power and gain settings. (B) High-throughput wide-field microscopy analysis of (A) in SH-SY5Y 
cells positive for III-tubulin expression (fig. S21A). The y axis shows PLC-1 MFI standardized to the median control level in the vehicle condition. Boxes show median and 
interquartile range, whiskers extend to extreme values within 1.5 × interquartile range, and dots mark data points outside this range. Each box plot represents data from 
an average of 8126 cells from three replicate experiments. Top 0.5% values lie outside of the plot area and were included in statistical analysis. P values from two-way 
ANOVA for interaction between the drug condition and the thapsigargin/PLC-1 response; FC represents potentiation of the thapsigargin/PLC-1 response in drug rela-
tive to control conditions and is calculated as (1 − response ratio in drug condition)/(1 − response ratio in control condition). Wide-field images were acquired at the same 
light source and detector settings at 20× magnification.
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mechanisms of action even when the pathological process is not fully 
understood. This model is amenable to DR such that therapeutic 
candidates with documented pharmacokinetic and safety profiles, for 
example, those presented for SCZ (Fig. 5C), can be readily validated 
in clinical trials. It also raises the possibility that the ex vivo cellular 
response phenotype could be used not only as a drug target but also 
as a companion biomarker predicting clinical efficacy in patient 
subpopulations (Fig. 7). The model helps to refine the generic indi-
cations suggested by GWAS and exome sequencing studies (such as 
T- and L-type calcium channel blockade for the treatment of SCZ) 
(7, 40, 51) by ranking which therapeutic class members best recapitulate 
the cellular hallmarks of in vivo efficacy. This information could 
prove useful for interpreting the heterogeneous clinical trial results 
obtained previously for calcium channel blockers in SCZ (51). 
While these clinical trials have shown potential therapeutic benefits 
of DHP L-type calcium channel blockers (51), the current results 
raise the possibility that the structural derivates with extended ester 
substitutions at the 3-position of the pyridine ring (nisoldipine and 
nicardipine), which have not yet been tested, could provide en-
hanced efficacy. This is supported by their in vitro activity in neu-
rons (Fig. 6) and initial studies of brain penetrance and the reversal of 
aberrant behavior in the phencyclidine animal model of SCZ using 
these compounds (52, 53). Furthermore, the cellular response pheno-
type serves to identify compounds from structurally unrelated drug 
classes that show similar effects on cell signaling, for example, cortico-
steroids (methylprednisolone and flunisolide) or a potassium channel 
blocker (ibutilide), thus expanding the mechanistic diversity of 
neuropsychiatric drug candidates at early stages in the drug discovery 
pipeline. Last, it provides potential insight into the functional impli-
cations of interactions between multiple common but weak (7) and 
rare but penetrant (36, 40) genetic risk loci at a time when the 
majority of heritable genetic risk has yet to be determined (4).
The second contribution of this work is the identification in 
peripheral T cells of differential interactions of neuropsychiatric 
medications at multiple cell signaling targets possibly predictive of 
CNS efficacy. The results indicate mechanistic points of convergence 
between neuropsychiatric drugs with different indications [e.g., 
antidepressants, mood stabilizers, and antipsychotics at 4EBP1 
(pT36/pT45); Fig. 2F] and divergent activities of neuropsychiatric 
drugs within the same indication [e.g., mood stabilizers such as lithium 
at 4EBP1 (pT36/pT45) and valproic acid at Rb (pS780) (Fig. 2F) 
or typical versus atypical antipsychotics at thapsigargin/PLC-1 
(fig. S20)]. This, together with individual variation in drug sensitivity 
between patients (Fig. 7A), raises the possibility of treatment 
response prediction through ex vivo testing of the drugs that are 
administered clinically (Fig. 7B and fig. S22A). This has the potential 
to circumvent the challenges of therapeutic uncertainty and the 
identification of nonresponders early in the treatment course (3, 4). 
Moreover, the results emphasize the importance of associating 
putative drug target efficacy with changes in specific subsets of clinical 
symptomatology, both in terms of characterizing the drug target itself 
and determining its predictive value for personalized medicine.
While several of the reported neuropsychiatric drug-target inter-
actions were already known, for example, at Akt/GSK-3 pathway 
epitopes (Fig. 3A) (32), others such as the induction of phosphoryl-
ation at CrkL (pY207) in response to antipsychotic administration 
ex vivo (Fig. 2F) and in vivo (Fig. 4) have not been previously 
reported, despite the emerging implication of the CRKL locus in 
genetic risk for SCZ (36). It is possible that these “off-target” effects 
may eventually be recognized as key components of therapeutic 
efficacy or alternatively toxicity. Therefore, their identification at 
early stages of the drug development pipeline could improve the 
efficiency of future drug discovery efforts. Moreover, the differential 
cell signaling signature of the approved medications may serve as 
a mechanistic scaffold to identify novel experimental drugs or 
repurposing candidates (e.g., JB1121 or rapamycin, respectively; 
Fig. 3). The ability to resolve pharmacological effects discretely at 
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Fig. 7. Correlation of ex vivo drug-target activity with in vivo efficacy. (A) Longitudinal clinical patient assessment of the in vivo efficacy of two antipsychotic medications 
(aripiprazole and risperidone), identified in the drug-screening phase (Fig. 5), on SCZ symptoms assessed using the SAPS in drug-naïve patients with SCZ (n = 12 and 
18 for aripiprazole and risperidone treatments, respectively) between treatment time points at 0 weeks (w) and 12 months (m). Treatments were equally efficacious (P > 0.05, 
two-way ANOVA). Patients remained on the same treatment at least until the 3-month time point. (B) Correlation between the ex vivo efficacy of the two antipsychotic 
medications (aripiprazole and risperidone), measured as the shift in EC50 (EC50) of the thapsigargin/PLC-1 response induced by the respective drug in PBMCs collected 
at baseline from individual patients with SCZ, and the in vivo efficacy in ameliorating positive symptoms (SAPS) after 3 weeks of clinical treatment in the same patients. 
Linear regression model with 95% confidence intervals, adjusted for covariates selected in stepwise procedure using Bayesian information criterion.
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possibility of exploiting synergistic interactions between highly specific 
ligands, such as CHIR-99021 (GSK-3 inhibitor) and rapamycin 
(mTORC1 inhibitor), to provide personalized combinatorial thera-
peutic options for neuropsychiatric disorders as a means to overcome 
treatment resistance (54).
This work aims to provide a proof-of-principle application of 
the novel drug discovery pipeline to neuropsychiatric disorders. 
However, there are several limitations relevant to future work. First, 
some of the cell signaling pathways interrogated in this screen are 
likely to respond differently in T cells versus CNS cells, consistent with 
cell lineage functional specificity. The aim of the study is therefore not 
to suggest that blood cells show an identical functional repertoire to 
neuronal or glial cells but to show that a subset of the pathways, or 
even individual protein-protein interactions, which do overlap, are 
clinically relevant and can be practically exploited for drug discovery 
and treatment response prediction. Given the high number of nodes 
afforded by high-content screening, even a small proportion of 
functional overlap could serve to identify a substantial number of 
novel targets that would, otherwise, not be available for functional 
exploration in primary neuropsychiatric patient cells. Nevertheless, 
as further ex vivo targets emerge, these will need to be carefully eval-
uated in CNS target tissues. Comparison of cell signaling responses 
between PBMCs and iPSC-derived CNS cells from the same patients 
offers a relevant opportunity in this respect. Moreover, although 
exogenous cellular stimulants have advantages in terms of receptor 
subtype specificity, potency, and heuristically targeting the maximum 
number of downstream signaling alterations in a limited clinical 
sample, disease-associated nodes identified using this approach 
require further characterization in the context of endogenous ligand 
responses. Second, the activity of second-generation antipsychotics 
at the target node, although not essential to the validity of the plat-
form, provides a useful positive control to support the initial target 
discovery, the drug screening candidates, and the clinical potential 
of the platform in terms of in vivo efficacy. It also helps to refine the 
targets of existing drugs while providing therapeutic candidates 
with divergent mechanisms of action, increased potencies, or 
reduced side effects. However, future studies would benefit from 
focusing on pretreatment differences in normal versus disease samples 
to identify targets that do not overlap with existing treatments. In 
this respect, the application of the platform to subgroups of patients 
with refractory symptom subtypes (e.g., cognitive symptoms) is 
essential to identifying drug candidates with long-term clinical 
superiority. Third, diagnostic uncertainty, disease heterogeneity, 
and dimensional overlap between related neuropsychiatric disorders 
(1, 2, 55) are persistent limitations in the current diagnostic framework 
used to define clinical groups. Nevertheless, as biological markers that 
reflect the etiology of neuropsychiatric disease (such those suggested 
by the present findings) are validated clinically, these diagnostic 
tools can potentially be improved in future studies. In this respect, it 
is notable that aberrant cellular responses to thapsigargin (56), associated 
genetic mutations in ATP2A2 (20), and manic-like behavioral 
changes following PLC-1 knockout in animal models (43) have 
also been reported in the context of bipolar disorder, suggesting 
that the identified primary drug target might show transdiagnostic 
potential for the treatment of related psychotic disorders. Fourth, 
the modest sample sizes used in the target identification study 
reflect difficulties in obtaining viable PBMCs from strictly defined 
drug-naïve first-onset neuropsychiatric patients, controlled for 
treatment status, and combined with a longitudinal in vivo treatment 
follow-up. Despite validation of the principal drug target in an 
independent cohort, future studies will benefit from the application 
of the ex vivo methodology in more extensive patient groups. Last, 
despite indications of efficacy in animal models (52, 53), a more 
extensive validation of the DR candidates is necessary to determine 
their clinical utility.
The present study represents, to our knowledge, the most extensive 
(3696 responses) functional characterization of cell signaling 
abnormalities in live primary cells from neuropsychiatric patients. 
In addition to providing a conduit for novel drug discovery and 
clinical treatment response prediction, in the form of phenotypic 
screening, it allows the reevaluation of the concept that neuropsy-
chiatric disorders involve composite dysregulation of whole canonical 
signaling pathways. Instead, current data suggest that cell signaling 
abnormalities are more complex and that aberrant responses appear 
sporadically, even in the case of broad spectrum signaling activators, 
at individual proteins within a tightly regulated network. The iden-
tification of specific stress points within these networks, which 
escape regulatory control (e.g., PLC-1), might ultimately prove more 
relevant for drug target discovery. In this respect, the incorporation 
of technologies such as mass cytometry (12, 31), high-dimensional 
computation [e.g., spanning-tree progression analysis of density- 
normalized events (57) and visualization by t-distributed stochastic 
neighbor embedding (58)], and combinatorial compound libraries 
(59) within the present workflow represents an unprecedented 
opportunity to explore causal relationships between cell signaling 
proteins and enhanced drug targets.
MATERIALS AND METHODS
Experimental design
The objective of this study was to identify functional drug targets in 
SCZ using patient primary blood cells and high-content phospho- 
specific flow cytometry and subsequently use the identified targets 
as a basis for DR and clinical treatment response prediction. This 
work was performed in four stages (Fig. 1). First, samples from 
eight healthy donors were analyzed in a time-course exploration of 
T cell responses to 70 ligands across 78 cell signaling epitopes (5460 
responses) to select the most active nodes and time point (KP; 
Fig. 1B). Next, responses to a selection of 56 ligands across 66 cell 
signaling epitopes (3696 in total) were compared across three clinical 
groups [healthy controls (n = 12), antipsychotic drug-naïve patients 
with SCZ (n = 12), and the same patients following 6 weeks of clinical 
treatment with the atypical antipsychotic olanzapine (n = 10)] to 
identify functional SCZ drug targets (TI; Fig. 1C). The identified 
target, attenuated response to thapsigargin at PLC-1, was then 
modeled in blood cells from healthy control donors (n = 6 to 12; 
limited clinical sample availability did not allow the use of patient 
PBMCs at this stage) and used for screening of 946 FDA-approved 
drugs (repurposing) and experimental neuropsychiatric compounds 
(extended FDA-approved DR; Fig. 1D), in addition to hypothesis- 
driven genotype association analysis between selected SCZ risk 
genes and target response. Last, the candidate compounds were 
validated in the SH-SY5Y human neuronal cell line (n = 3 replicates) and 
blood cells from an independent cohort of drug-naïve patients with 
SCZ (n = 30) treated with two of the study compounds, aripiprazole 
and risperidone, to investigate the relationship between the ex vivo 
and in vivo drug efficacy (CV; Fig. 1E). Methods relevant to specific 
substudies (KP, TI, DR, and CV) are indicated by abbreviations. All 
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samples were randomized across different plate positions and 
experimental days to minimize measurement-related batch effects. 
To allow randomization, investigators were not blinded to sample 
characteristics. Samples in which the lymphocyte gate contained 
less than 30% of events (e.g., because of low viability; one sample in 
the TI study) were excluded from statistical analysis. Data permutation 
procedures (n = 10,000 permutations) were applied to control for 
small sample sizes, non-normal distribution of data, presence of 
outliers, and simultaneous testing of multiple hypotheses. Sample 
sizes were based on the availability of viable PBMCs from strictly 
defined drug-naïve first-onset patients with SCZ, controlled for 
treatment status and with longitudinal in vivo treatment follow-up 
information available, as well as previous studies (12, 31). At 12 versus 
12 and with a 20% coefficient of variation, the TI study was suffi-
ciently powered (0.8) to detect a 23% difference between the groups 
at  = 0.05.
Clinical sample recruitment
For the KP and DR studies, healthy control PBMC donors were 
recruited at the Cambridge Centre for Neuropsychiatric Research 
(CCNR), University of Cambridge, UK. For the TI study, first-onset 
antipsychotic drug-naïve male patients with SCZ before (n = 12) 
and the same patients after (n = 10) 6 weeks of treatment with the 
atypical antipsychotic medication olanzapine (10 to 20 mg/day), in 
addition to matched controls (n = 12), were recruited at the Department 
of Psychiatry, Erasmus Medical Centre, Rotterdam, the Netherlands 
(table S5). For the CV study, first-onset antipsychotic drug-naïve 
patients with SCZ (n = 30) were recruited at the University Hospital 
Marqués de Valdecilla, Santander, Spain (table S10). These patients were 
subsequently treated with the antipsychotic medication aripiprazole 
(n = 12; 5 to 30 mg/day) or risperidone (n = 18; 2 to 4 mg/day). The 
medical faculty ethical committees responsible for the respective 
sample collection sites approved the study protocols. Informed consent 
was given in writing by all participants, and clinical investigations 
were conducted according to the Declaration of Helsinki and Standards 
for Reporting of Diagnostic Accuracy.
Diagnoses of neuropsychiatric pathology were conducted by 
experienced psychiatrists and were based on the Diagnostic and 
Statistical Manual of Mental Disorders–IV–Text Review. The severity 
of symptom subtypes in SCZ was measured using the Positive and 
Negative Syndrome Scale (TI) or the SAPS and the Scale for the 
Assessment of Negative Symptoms (CV). The exclusion criteria for 
patients and controls included as follows: additional neuropsychiatric 
diagnoses other than SCZ, other neurological disorders including 
epilepsy, mental retardation, multiple sclerosis, immune/autoimmune 
disorders, infectious disease, metabolic disorders including diabetes, 
obesity, cardiovascular disease, hepatic and renal insufficiency, 
gastrointestinal disorders, endocrine disorders including hypo-/
hyperthyroidism and hypo-/hypercortisolism, respiratory diseases, 
cancer, severe trauma, substance abuse including psychotropic drugs 
and alcohol, somatic medication with brain side effects, and somatic 
medication affecting the immune system including glucocorticoids, 
anti-inflammatory/immunomodulating drugs, and antibiotics.
PBMC isolation and culture
PBMCs were prepared within 4 hours from blood collected into 7.5-ml 
sodium heparin tubes (BD Biosciences; KP, TI, and DR) or acid 
citrate dextrose solution A tubes (BD Biosciences; CV). Whole 
blood was pelleted at 500g for 10 min to remove platelet-rich plasma, 
diluted 1:1 with Dulbecco’s phosphate-buffered saline solution 
(PBS; Sigma-Aldrich), and centrifuged over Ficoll-Paque PLUS (GE 
Healthcare) at 750g for 20 min at 23°C. PBMCs were extracted from 
the interphase, washed three times with PBS at 300g for 10 min, and 
cryopreserved at 5 × 106 cells/ml in heat-inactivated fetal bovine 
serum (FBS; Sigma-Aldrich) containing 10% dimethyl sulfoxide 
(DMSO; Sigma-Aldrich). For cell culture, PBMCs were thawed at 
37°C and resuspended in sterile conditions in complete RPMI media 
with deoxyribonuclease (DNAse) [RPMI-1640 with sodium bi-
carbonate (Sigma-Aldrich), 10% FBS (Life Technologies), penicillin 
(50 U/ml) and streptomycin (50 g/ml; Life Technologies), 2 mM 
l-alanyl-l-glutamine dipeptide (Life Technologies), and DNAse (20 g/ml; 
Sigma-Aldrich)]. The cells were counted using a Coulter counter 
(Beckman Coulter), pelleted, and resuspended at 1 × 106 cells/ml. 
The cells were rested for 24 hours at 37°C/5% CO2 either in cell 
culture flasks (Corning; KP and TI) or, via a 40-m cell strainer 
(Corning), in 96-well polypropylene plates (StarLab; DR and CV). 
Samples from participants from different clinical groups, alongside 
quality control (QC) samples from healthy control donors, were 
randomized across different plate positions and experimental days 
to minimize measurement-related batch effects.
Preparation of functional ligands and compound libraries
Ligands used to stimulate PBMCs (including cell signaling activators/
inhibitors and receptor agonists/antagonists) were purchased from 
Sigma-Aldrich, Tocris/Bio-Techne, eBioscience/Affymetrix, R&D 
Systems, Life Technologies, Abcam, Antibodies-online, and Enzo 
Life Sciences. CHIR-99021 and JB1121 were synthesized in-house 
following published protocols (33). Table S2 lists the ligands used 
with their primary mechanisms of action and final assay concentrations 
(selected on the basis of published in vitro efficacy data and maximal 
clinical serum concentrations in the presence of serum proteins 
where relevant). Stock solutions of ligands were prepared in sterile 
conditions. Initial solubilization was achieved using DMSO where 
possible and, alternatively, PBS, H2O, or H2O with equimolar NaOH 
as per the manufacturer’s instructions. Intermediate dilutions were 
made in PBS, and DMSO was added to equivalent amounts for each 
ligand and vehicle.
The FDA-approved compound library (v.2.0; Enzo Life Sciences) 
was extended to incorporate experimental compounds contributed 
by collaborators [L. Jones-Brando, R. Yolken, G. H. Posner, 
J. G. D’Angelo, and C. P. Hencken (Johns Hopkins University School of 
Medicine, Baltimore, MD, USA); J. McNulty (McMaster University, 
Hamilton, Ontario, Canada); F. F. Wagner and E. B. Holson (Broad 
Institute of MIT and Harvard, MA, USA); T. L. Petryshen and 
S. J. Haggarty (Massachusetts General Hospital, Boston, MA, USA); 
and R. S. Williams (Royal Holloway University of London, Egham, 
UK)] and also positive controls/neutraceuticals, related to putative 
drug targets, from the CCNR compound library (table S8). Initial 
solubilization was conducted using DMSO where possible and, 
alternatively, PBS or H2O as per the manufacturer’s instructions. 
Intermediate dilutions were prepared using complete RPMI media 
without penicillin-streptomycin [RPMI-1640 with sodium bi-
carbonate (Sigma-Aldrich), 10% FBS (Life Technologies) to ac-
count for physiological serum protein binding of drugs, and 2 mM 
l-alanyl-l-glutamine dipeptide (Life Technologies)]. DMSO was 
added to equivalent amounts across all compounds and the vehicle. The 
final assay concentration of most of the compounds in the extended 
FDA-approved library was 20 M with some exceptions in the 
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compounds from collaborators and the CCNR library (table S8). All 
stocks and dilutions of stimulants and compounds were stored at 
−80°C, and repeated freeze-thaw cycles were avoided.
Stimulation of PBMCs
Stimulation is defined broadly as the exposure of PBMC cells to a 
ligand that has the potential to perturb resting-state cell signaling 
dynamics by either increasing or decreasing the expression of cell 
signaling epitopes. PBMCs were pelleted and resuspended [via 30-m 
cell strainer (Partec) for KP and TI studies] in 96-well polypropylene 
plates using complete RPMI media without penicillin-streptomycin 
at 2 × 106 cells/ml (KP), 0.75 × 106 cells/ml (TI), and 0.4 × 106 cells/ml 
(DR and CV). The cells were rested for 75 min (KP and TI) or 
45 min (DR and CV) at 37°C before ligand exposure. For the DR 
and CV studies, this resting period was used to preincubate the cells 
with the extended FDA-approved library compounds and screening 
hits, respectively, before stimulation. A standardized sample amount 
of 5.25 × 106 PBMCs per donor was used in the TI study, and no 
significant differences were observed in T cell frequencies between 
the control (67.1 ± 12.9%), pretreatment (72.0 ± 11.9%), and post-
treatment (74.0 ± 9.8%) SCZ groups (P > 0.27; Wilcoxon rank sum 
and signed-rank tests).
Stimulants and vehicle were reconstituted in complete RPMI 
media without penicillin-streptomycin and added to the cells using 
a Biomek NX liquid handler (Beckman Coulter) with an integrated 
compact shaker-heater-cooler system (Inheco). The final concen-
trations of DMSO in all conditions including vehicle were 0.1% (KP and 
TI) and 0.2% (DR and CV). Vehicle wells represented one-eighth 
of the total wells assayed (KP and TI), one-sixth of the total wells 
assayed (DR), or one-quarter of the total wells assayed (CV) and 
were spaced evenly across each 96-well plate. The cells were ex-
posed to the stimulants at 37°C for 1, 5, 15, and 30 min (KP) or 
30 min (TI, DR, and CV). Ligand exposure was halted by fixation 
for 10 min at 37°C using paraformaldehyde (Sigma-Aldrich) in PBS 
at a final concentration of 1.6%.
Fluorescent cell barcoding
Stock solutions of barcoding dyes CBD 450 (BD Biosciences), CBD 
500 (BD Biosciences), and DL800 (Thermo Fisher Scientific) were 
prepared as per the manufacturer’s instructions in DMSO in poly-
propylene 96-well plates and stored at −80°C. Different combinations 
of these dyes were used to produce a different number of barcoded 
cell populations specific to each study as follows. For the KP study, 
80 populations were resolved using final concentrations of CBD 450 
(0.000, 0.015, 0.075, and 0.300 mg/ml) combined with CBD 500 
(0.000, 0.038, 0.188, and 0.750 mg/ml) and DL800 (0.000, 0.011, 
0.033, 0.100, and 0.300 g/ml; figs. S1 and S2). For the TI study, 64 
barcoded populations were resolved using final concentrations of 
CBD 450 (0.000, 0.015, 0.050, and 0.150 mg/ml) combined with 
CBD 500 (0.000, 0.038, 0.125, and 0.375 mg/ml) and DL800 (0.000, 
0.017, 0.050, and 0.150 g/ml; fig. S10). For the DR study, four pop-
ulations were resolved using final concentrations of DL800 (0.000, 
0.017, 0.050, and 0.150 g/ml; fig. S16). Cells in the CV study were 
not barcoded and treated with the vehicle (PBS) instead.
Fixed cells were washed with PBS and permeabilized in 100 l of 
ice-cold methanol (Fisher Chemical) for 20 min at 2°C using a 
Biomek NX liquid handler to allow penetration of antibodies 
against intracellular epitopes. The barcoding dyes were diluted in 
ice-cold PBS and 100 l per well added to the suspension of cells in 
methanol. The final concentration of DMSO from the barcoding 
dyes at this stage was 3.5%. The barcoding reaction was incubated 
in the dark for 30 min at 2°C, and the cells were washed five (KP and 
TI) or four times (DR and CV) in ice-cold fluorescence-activated 
cell sorting (FACS) buffer [PBS with 0.5% bovine serum albumin 
(Sigma-Aldrich)]. The barcoding wells were pooled, washed, and 
resuspended at 1 × 106 cells/ml in FACS buffer for staining.
Intracellular staining of cell signaling epitopes in 
PBMC subsets
The suspension of fixed, permeabilized, barcoded cells was stained 
using either anti-human CD3 (UCHT1) phycoerythrin (PE)– cyanine 7 
(Cy7) (0.5 l/ml; eBioscience; KP and TI) or anti-human CD3 
(UCHT1) allophycocyanin (APC) (1 l/ml; eBioscience; DR and 
CV) and distributed across a 96-well polypropylene plate. The cells 
were stained using a Biomek NX liquid handler (Beckman 
Coulter) with fluorescently conjugated anti-human antibodies against 
intracellular signaling epitopes (table S1) for 45 min in the dark 
at room temperature, as per the manufacturer’s instructions. 
Antibodies were purchased from BD Biosciences, Cell Signaling 
Technology, Merck Millipore, and Bioss. Antibodies against in-
tracellular epitopes were used either individually (KP, DR, and 
CV) or in groups of three antibodies per plex (TI). The cells were 
washed twice and resuspended in FACS buffer at 1 × 106 cells/ml for 
acquisition.
Immunophenotyping and cell viability
PBMCs were resuspended at 1 × 106 cells/ml in FACS buffer with 
20% human Fc receptor–binding inhibitor (eBioscience) and incubated 
for 20 min at room temperature in 5-ml polystyrene FACS tubes 
(BD Biosciences). The PBMCs were stained in a total volume of 135 l 
per tube with 0.5 l of anti-human CD3 (UCHT1) PE-Cy7 (eBioscience), 
0.5 l of anti-human CD4 (SK3) PerCP-eFluor 710 (eBioscience), 
0.5 l of anti-human CD8 (SK1) APC-eFluor780 (eBioscience), and 
anti-human CD14 (MφP9) V500 (BD Biosciences). The cells were 
incubated in the dark for 30 min at room temperature. They were 
washed twice with 3 ml of FACS buffer and resuspended in 0.5 ml 
of FACS buffer with 1 M 4′,6-diamidino-2-phenylindole (DAPI; 
Sigma-Aldrich) (fig. S11).
Data acquisition using flow cytometry
PBMC suspensions were acquired using an eight-color FACSVerse 
flow cytometer (BD Biosciences) with 405-, 488-, and 640-nm laser 
excitations at an average flow rate of 2 l/s and an average threshold 
event rate of 1000 to 2000 events/s. Multicolor Cytometer Setup and 
Tracking beads (BD Biosciences) were used for QC and standard-
ization of photomultiplier tube detector voltages across multiple 
experimental runs. Fluorescence compensation for immunopheno-
typing was conducted using anti-mouse immunoglobulin G (IgG) 
antibody capture beads (Bangs Laboratories) labeled separately with 
each antibody. Fluorescence compensation for intracellular staining of 
cell signaling epitopes was conducted using anti-mouse IgG antibody 
capture beads labeled separately with anti-human CD3 (UCHT1) PE-Cy7 
(eBioscience), anti-human Stat3 (pY705) (4/P-STAT3) Alexa Fluor 
488 (AF 488; BD Biosciences), anti-human Stat3 (pY705) 
(4/P-STAT3) PE (BD Biosciences), and anti-human Stat3 (pY705) 
(4/P-STAT3) AF 647 (BD Biosciences; KP and TI) or anti-human 
CD3 (UCHT1) APC (eBioscience) and PLC-1 (10/PLCgamma) PE 
(BD Biosciences; DR and CV), alongside single-stain controls with 
Lago et al., Sci. Adv. 2019; 5 : eaau9093     8 May 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
15 of 18
maximum and minimum concentrations of each barcoding dye per 
PBMC sample.
Genotype analysis
Genotyping data from the CV samples (table S10) were obtained 
using the Illumina Infinium PsychArray Bead-Chip platform. SCZ 
risk SNPs related to calcium signaling were selected for analysis 
based on previous reports (7) and included variants in the ATP2A2 
(rs4766428), CACNA1C (rs2159100, rs2007044, and rs758117), 
CACNB2 (rs7893279), CACNA1I (rs5757730), CALN1 (rs2944823), 
NLGN4X (rs12845396), RIMS1 (rs1339227), and TMEM110 
(rs2535627) genes. For SNPs not included in the Illumina Infinium 
PsychArray Bead-Chip array (rs758117, rs7893279, rs12845396, 
and rs1339227), we used the LDproxy tool of LDlink (60) and the 
1000 Genomes European population as a reference to identify mea-
sured SNPs that were in the highest linkage disequilibrium (R2 > 0.8) 
with the SNPs of interest (rs10491964, R2 = 0.93; rs4748466, R2 = 0.85; 
rs12835663, R2 = 0.83; and rs2789588, R2 = 0.82, respectively) and 
analyzed them as a proxy. Association between response to thapsigargin 
at PLC-1, expressed as the EC50, and the number of SCZ risk 
alleles per individual was assessed using fixed-effects linear regres-
sion (one-tailed test; H0,  ≤ 0; H1,  > 0) adjusted for age, gender, 
and body mass index (BMI). P values were obtained by permutation 
testing (n = 1000 permutations).
SH-SY5Y cell culture, stimulation, and microscopy
The SH-SY5Y human neuronal cell line (passage 5; European Collec-
tion of Authenticated Cell Cultures) was thawed at 37°C and seeded in 
cell culture flasks (Thermo Fisher Scientific) at approximately 0.1 M/ml 
in minimum essential medium (MEM)/F12 culture medium [1:1 MEM 
(Sigma-Aldrich) with 1% antibiotics (penicillin-streptomycin, Life 
Technologies) and Ham’s F12 nutrient mixture (Sigma-Aldrich) 
with 1% penicillin-streptomycin, 15% FBS (Life Technologies), 
1% nonessential amino acids (Sigma-Aldrich), and 1% GlutaMAX 
(Life Technologies)]. Cells were rested overnight at 37°C/5% CO2, 
and the medium was changed the following day. The cells were cul-
tured until reaching 70 to 75% confluence. For passaging, the cells were 
washed twice with MEM containing 1% penicillin-streptomycin 
and trypsinized using trypsin-EDTA (Life Technologies) for 5 min 
at 37°C, diluted with fresh culture medium, and centrifuged at 300g 
for 5 min. The cells were resuspended at approximately 0.3 M/ml 
in the culture medium and seeded into T75 flasks (Thermo Fisher 
Scientific). The medium was changed the next day after each passage. 
Cells were stored in liquid nitrogen in medium with 10% DMSO 
(Sigma-Aldrich).
Cells from passage 11 were used for DR microscopy experiments. 
Each experiment was performed in triplicate. The cells were seeded 
at 0.1 M/ml in 96-well imaging plates (Corning) and cultured for 48 
hours at 37°C/5% CO2. Medium was changed 24 hours before stim-
ulation experiment. Stimulation for 30 min was performed as in 
PBMCs using MEM/F12 culture medium without antibiotics in 
place of complete RPMI medium without antibiotics. Fixed cells 
were washed with PBS and permeabilized using 85 l of ice-cold 
methanol for 20 min on ice, followed by addition of 85 l of ice-cold 
PBS for another 30 min. The cells were washed three times with 
FACS buffer and stained with anti--tubulin class III AF 647 (50 l/ml; 
BD Biosciences) and anti-human PLC-1 PE (300 l/ml; BD Bio-
sciences) in FACS buffer for 24 hours at 4°C. The cells were then 
washed three times with FACS buffer and stained with 3 M DAPI 
(Sigma-Aldrich) in FACS buffer for 15 min at room temperature. 
The cells were washed once with FACS buffer and resuspended in 
FACS buffer for analysis.
Imaging was performed using confocal (LSM 710, Zeiss) and 
wide-field (DMI6000 with matrix HCS module, Leica) microscopy. For 
confocal imaging, laser excitation/fluorescence detection wavelengths 
were 405 nm/431 to 500 nm for DAPI, 543 nm/549 to 614 nm for 
PE, and 633 nm/644 to 708 nm for AF 647. For wide-field imaging, 
excitation/detection filters were DAPI/DAPI for DAPI, TRITC (tet-
ramethyl rhodamine isothiocyanate)/TRITC for PE, and Cy5/Cy5 
for AF 647. All replicate experiments were performed simulta-
neously and analyzed with identical laser/excitation power and gain 
settings.
Statistical analysis
Flow cytometry data were analyzed in flow cytometry standard 3.0 
file format using FlowJo v.10.0.8 (TreeStar) and Kaluza Analysis 
v.1.3 (Beckman Coulter) software. Microscopy data were analyzed 
using CellProfiler Analyst v.2.0 (Broad Institute) and Fiji ImageJ 
1.51n (National Institutes of Health). Statistical analysis was con-
ducted using R software (R Core Team). PBMC samples in which 
the lymphocyte gate contained less than 30% of events, measured by 
forward scatter/side scatter, were excluded from further analysis. 
Individual treatment-epitope combinations (nodes) for which there 
were fewer than four data points (i.e., four PBMC samples), in the 
KP and DR studies, or fewer than eight data points (i.e., eight PBMC 
samples), in the TI study, were excluded from further analysis. 
Batch effects in MFIs caused by running samples on different days were 
removed for each epitope (TI) using the empirical Bayes algorithm— 
ComBat (R “sva” package). Experimental variables including posi-
tional effects within and across 96-well plates, barcoding dye fluo-
rescence spillover, sample viability, cell counts, clinical group, and 
sample source were controlled for by principal components and 
Z factor analysis. Matching of clinical groups was conducted using the 
Wilcoxon rank sum test for continuous variables or the Fisher’s exact 
test for categorical variables.
For the determination of stimulant activity, the MFIs across 
PBMC samples, per stained epitope, were compared between each 
stimulant and the vehicle treatment using the conditional Wilcoxon 
rank sum test using the exact distribution for obtaining the P value 
(R “coin” package). The same test was also applied for each stimu-
lant per functional fluorescence channel (AF 488, PE, and AF 647) in 
the unstained condition to determine whether the stimulant activity was 
an artifact of fluorescence spillover from adjacent channels or ligand 
autofluorescence (background fluorescence). In cases where the stim-
ulant MFI was significantly altered with respect to vehicle MFI in 
the unstained condition, the epitopes labeled in the corresponding 
functional channel were only counted as active if the MFI response 
was in a different direction or had a 10% greater FC than the un-
stained condition. For stimulants with significant activity (permuted 
P < 0.05, Wilcoxon rank sum test) that superseded the background 
fluorescence, the response ratio was quantified as the median MFI 
of the stimulant divided by the median MFI of the vehicle across 
PBMC samples. For responses <1 (i.e., where the stimulant caused a 
decrease in MFI with respect to the vehicle), the response is reported 
as a negative FC (−1 divided by response ratio). The stain index of each 
antibody was calculated across PBMC samples, in the absence of 
stimulation, as the median MFI of the antibody stained sample 
divided by the median MFI of the corresponding unstained control. 
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The two-tailed Spearman’s rank test was used to assess the correlation 
in FC responses for nodes replicated in independent experiments.
In the TI study, association of each active signaling node MFI to 
clinical group status was investigated using linear fixed-effects 
regression after adjusting for covariates. Active nodes were defined 
as those with a minimum epitope stain index of two and additionally, 
for ligand responses, a significant FC (P < 0.05, Wilcoxon rank sum 
test) of minimum 10% in at least one of the comparison groups, 
after adjusting for background fluorescence. Inactive nodes were 
excluded from the clinical group comparison analysis. The predictive 
variables of clinical group and ligand presence were set as interaction 
terms within the regression model to determine epitopes, which 
responded differently to individual ligand exposures across the clinical 
groups. Group status, without interaction, was set as the predictive 
variable to identify differences in basal epitope expression between 
clinical groups. Optional covariates, age and BMI (plus smoking 
and alcohol consumption in sensitivity analyses), were selected in the 
regression model in a stepwise procedure for each node separately 
using Bayesian information criterion. The mean of eight measure-
ments in the vehicle condition and a single measurement in the 
stimulant condition per donor were used for the analysis. To ac-
count for the unknown distribution of the data, the small sample 
size, and the presence of outliers, the null distribution of the test 
statistic was estimated by randomly permuting sample labels 10,000 
times for each node. Q values (P values corrected for multiple 
hypothesis testing) were calculated as the proportion of the permu-
tation distribution for the maximal statistic that was greater than or 
equal to the originally obtained statistic.
In the DR study, association of PLC-1 MFI to compound and 
stimulant status was investigated using permutation-based linear 
fixed-effects regression (n = 10,000 permutations). The predictive 
variables of stimulant group (thapsigargin or vehicle) and compound 
exposure (compound or vehicle) were set as interaction terms within 
the regression model to determine compounds that modified the 
PLC-1 response to thapsigargin. For compounds that showed a 
significant interaction with the stimulant (permuted P < 0.05), post 
hoc one-way ANOVA tests and median values were used to determine 
the directionality of the effects. The same model (nonpermuted, 
due to large number of data points) was applied to neuronal DR 
validation data. In the validation experiments, dose-response data 
were fitted with four-parameter (thapsigargin dose-response exper-
iments) or five-parameter (drug dose-response experiments) logis-
tic regression models [R “nplr” package and GraphPad Prism 5 
(GraphPad Software)].
In the CV study, ex vivo response to treatment, the shift in 
thapsigargin/PLC-1 EC50 (EC50), was calculated as the difference in 
EC50 between the drug and vehicle conditions. In vivo response to treat-
ment was calculated as the difference between basal and follow-up 
(3 weeks, 6 weeks, and 3 months) symptoms. Association between 
the ex vivo and in vivo responses to treatment was investigated 
using linear fixed-effects regression, after adjusting for covariates. 
Optional covariates, basal symptoms, treatment drug, age, gender, 
and BMI, were selected in the regression model in a stepwise procedure 
for each correlation separately using Bayesian information criterion. 
The null distribution of the test statistic was estimated by randomly 
permuting sample labels 10,000 times for each correlation. Q values 
were calculated as the proportion of the permutation distribution for 
the maximal statistic that was greater than or equal to the originally 
obtained statistic. Dose-response data were fitted with four-parameter 
logistic regression model. Data were visualized using FlowJo v.10.0.8, 
Kaluza Analysis v.1.3, R software, GraphPad Prism 5, Excel 2016 
(Microsoft), PubChem (National Center for Biotechnology Infor-
mation), Fiji, and Adobe Illustrator (Adobe Systems).
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